Axovant Sciences (AXON) PT Raised to $190 at Needham & Company

February 26, 2021 7:42 AM EST
Get Alerts AXON Hot Sheet
Price: $151.00 +0.30%

Rating Summary:
    6 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 5 | Down: 16 | New: 67
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Scott Berg raised the price target on Axovant Sciences (NASDAQ: AXON) to $190.00 (from $130.00) while maintaining a Buy rating.

The analyst commented, "Axon reported much better than expected 4Q sales results driven by a large international TASER7 transaction and additional TASER7 sales into newer markets. As a result, the strong sales drove a quarterly best 28.7% adjusted EBITDA margins in over six years. We remain enamored with the company's expanding TAM and believe that the company's FY21 planned $25mm in for additional manufacturing capacity and automation is a strong signal that elevated TASER7 demand can last into at least FY23. We believe the market may be disappointed initially by FY21 guidance calling for only 12% revenue growth versus the strong FY19 and FY20 results, but we believe the guidance is appropriately conservative on large transactions whose timing is unpredictable."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Needham & Company